SRR1078879
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.589
- OXIDATIVE_PHOSPHORYLATION+0.543
- INTERFERON_GAMMA_RESPONSE+0.351
- FATTY_ACID_METABOLISM+0.346
- MTORC1_SIGNALING+0.336
- IL2_STAT5_SIGNALING+0.335
- INFLAMMATORY_RESPONSE+0.328
- ADIPOGENESIS+0.317
- UV_RESPONSE_UP+0.311
- INTERFERON_ALPHA_RESPONSE+0.308
Top 10 suppressed
- G2M_CHECKPOINT-0.333
- WNT_BETA_CATENIN_SIGNALING-0.286
- E2F_TARGETS-0.249
- HEDGEHOG_SIGNALING-0.219
- UV_RESPONSE_DN-0.219
- NOTCH_SIGNALING-0.194
- KRAS_SIGNALING_DN-0.135
- MITOTIC_SPINDLE-0.098
- SPERMATOGENESIS-0.058
- TGF_BETA_SIGNALING-0.036
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_8Z3SCKB5 | subependymal giant cell astrocytoma(SEGA) | — | 0.895 |
| 2 | BS_JG9JZTA9 | low-grade glioma | — | 0.889 |
| 3 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.874 |
| 4 | BS_3TQSE8HF | subependymal giant cell astrocytoma(SEGA) | — | 0.873 |
| 5 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.866 |
| 6 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.863 |
| 7 | BS_R634WKN7 | subependymal giant cell astrocytoma(SEGA) | — | 0.861 |
| 8 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.856 |
| 9 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.855 |
| 10 | MNG228 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.589 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.543 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.351 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.346 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.336 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.335 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.328 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.317 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.311 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.308 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.307 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.293 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.286 | Inavolisib | — uncovered |
| COMPLEMENT | 0.279 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.259 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.249 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.249 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.246 | Idelalisib | — uncovered |
| PEROXISOME | 0.246 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.246 | Inavolisib | — uncovered |